Aditx Therapeutics (ADTX)
(Delayed Data from NSDQ)
$0.27 USD
-0.11 (-29.69%)
Updated Sep 23, 2024 04:00 PM ET
After-Market: $0.26 -0.01 (-3.35%) 5:12 PM ET
NA Value
NA Growth NA Momentum NA VGMBrokerage Reports
0 items in cart
Aditxt Inc. [ADTX]
Reports for Purchase
Showing records 1 - 20 ( 23 total )
Company: Aditxt Inc.
Industry: Medical - Drugs
Company: Aditxt Inc.
Industry: Medical - Drugs
Company: Aditxt Inc.
Industry: Medical - Drugs
Aditxt (ADTX)-Neutral Rated: Acquires MDNA We Spoke with Management ? It?s a Good Deal
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: KOLBERT J
Company: Aditxt Inc.
Industry: Medical - Drugs
Company: Aditxt Inc.
Industry: Medical - Drugs
Company: Aditxt Inc.
Industry: Medical - Drugs
ADI-100 to Enter Clinic Near-Term; 2Q23 Financials; Raising PT to $61
Provider: H.C. Wainwright & Co., Inc.
Analyst: KAPOOR M
Company: Aditxt Inc.
Industry: Medical - Drugs
Company: Aditxt Inc.
Industry: Medical - Drugs
Neutral Rated- Cash Versus Catalysts - Stay Tuned
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: KOLBERT J
Company: Aditxt Inc.
Industry: Medical - Drugs
3Q22 Financial Results Reported; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: KAPOOR M
Company: Aditxt Inc.
Industry: Medical - Drugs
Personalizing Precision Immunological Therapy; Initiating at Buy and $4 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: KAPOOR M
Company: Aditxt Inc.
Industry: Medical - Drugs
Neutral Rated - Announces the initiation of GMP manufacturing for ADI-100
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: KOLBERT J
Company: Aditxt Inc.
Industry: Medical - Drugs
Lowering to Neutral from Buy, As Aditxt Announces a 50:1 Stock Split
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: KOLBERT J
Company: Aditxt Inc.
Industry: Medical - Drugs
BUY: Reports 2nd Quarter ? Cash is Tight, We Expect a Capital Raise. We are Lowering our Price Target from $6.0 to $1.0
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: KOLBERT J
Company: Aditxt Inc.
Industry: Medical - Drugs
BUY: Why Do We Like Aditxt - Introducing Our Webinar Series - An Open One Hour Discussion with CEO Amro Albanna
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: KOLBERT J
Company: Aditxt Inc.
Industry: Medical - Drugs
BUY: An Intermediate Step Towards the Acquisition
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: KOLBERT J
Company: Aditxt Inc.
Industry: Medical - Drugs
BUY: One Stop Shopping: Point of Care & A Therapeutic Too
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: KOLBERT J
Company: Aditxt Inc.
Industry: Medical - Drugs
BUY: Reports 3Q21; Raises Capital but No revenues Yet, Lowering Price Target to $4.00 from $8.00
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: KOLBERT J
Company: Aditxt Inc.
Industry: Medical - Drugs
Company: Aditxt Inc.
Industry: Medical - Drugs
BUY: Reports Second Quarter; Lowering Target to $8 from $14
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: KOLBERT J
Company: Aditxt Inc.
Industry: Medical - Drugs
BUY: High Sensitivity Anti-Body Test to COVID Launched
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: KOLBERT J